The impact of mismatch repair deficiency (MRD) on survival of temozolomide (TMZ)-treated patients with MGMT methylated (m-MGMT) glioblastoma (GBM): a Cellworks computational biosimulation pilot study
Neuro-Oncology Cellworks Study identifies biomarkers for TMZ resistance in m-MGMT GBM patients 2022 Glioblastoma Multiforme
READ MORE